OpenAI has released an updated version of its GPT-Rosalind series, designed to support life sciences research at an enterprise scale. The new model integrates GPT-5.5’s coding and tool-use features with enhanced intelligence in drug discovery and genomics, improving performance across a range of scientific workflows. This update aims to better address the complex challenges of life sciences research by incorporating data from multiple scales and modalities, including molecules, genes, and biological systems. Source: openai
To measure the real-world impact of GPT-Rosalind, OpenAI developed LifeSciBench, an expert-judged benchmark focused on foundational aspects of life sciences research. Unlike existing benchmarks, LifeSciBench evaluates tasks from six central workflow areas, including evidence handling, analysis, design, and scientific reasoning. This benchmark helps align model improvements with the practical needs of researchers and industry experts. Source: openai
The updated GPT-Rosalind has shown strong performance across scientifically valuable tasks identified by experts in the life sciences field. The model is now available in research preview to eligible organizations globally through a trusted-access deployment structure. Source: openai
